Janney Montgomery Scott LLC Purchases New Stake in Bioverativ Inc (BIVV)

Janney Montgomery Scott LLC purchased a new stake in Bioverativ Inc (NASDAQ:BIVV) during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 13,781 shares of the biotechnology company’s stock, valued at approximately $786,000.

Several other large investors have also modified their holdings of BIVV. Ladenburg Thalmann Financial Services Inc. acquired a new stake in Bioverativ during the third quarter worth about $190,000. Cubist Systematic Strategies LLC acquired a new stake in Bioverativ during the third quarter worth about $1,470,000. Point72 Asset Management L.P. acquired a new stake in Bioverativ during the third quarter worth about $8,047,000. ValueAct Holdings L.P. acquired a new stake in Bioverativ during the third quarter worth about $72,514,000. Finally, Sarissa Capital Management LP acquired a new stake in Bioverativ during the third quarter worth about $66,486,000. 95.99% of the stock is currently owned by institutional investors.

Bioverativ Inc (BIVV) opened at $54.04 on Friday. Bioverativ Inc has a one year low of $40.00 and a one year high of $64.41. The stock has a market cap of $5,860.00 and a P/E ratio of 13.21.

Bioverativ (NASDAQ:BIVV) last posted its earnings results on Thursday, October 26th. The biotechnology company reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.55 by $0.25. Bioverativ had a net margin of 40.44% and a return on equity of 69.03%. The company had revenue of $291.60 million during the quarter, compared to analysts’ expectations of $285.45 million. The business’s revenue for the quarter was up 27.2% compared to the same quarter last year. equities analysts expect that Bioverativ Inc will post 2.45 earnings per share for the current fiscal year.

A number of research firms recently weighed in on BIVV. Piper Jaffray Companies reissued an “overweight” rating and set a $71.00 target price on shares of Bioverativ in a research report on Monday, October 23rd. Zacks Investment Research upgraded shares of Bioverativ from a “hold” rating to a “strong-buy” rating and set a $69.00 price target for the company in a research note on Thursday, October 19th. Morgan Stanley restated an “underweight” rating and set a $47.00 price target (up previously from $45.00) on shares of Bioverativ in a research note on Friday, October 6th. Royal Bank of Canada assumed coverage on shares of Bioverativ in a research note on Thursday, September 14th. They set a “sector perform” rating and a $59.00 price target for the company. Finally, Argus upgraded shares of Bioverativ from a “hold” rating to a “buy” rating and set a $64.00 price target for the company in a research note on Wednesday, September 20th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Bioverativ presently has an average rating of “Hold” and a consensus price target of $60.93.

ILLEGAL ACTIVITY WARNING: “Janney Montgomery Scott LLC Purchases New Stake in Bioverativ Inc (BIVV)” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.com-unik.info/2017/12/24/janney-montgomery-scott-llc-purchases-new-stake-in-bioverativ-inc-bivv.html.

Bioverativ Profile

Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.

Want to see what other hedge funds are holding BIVV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bioverativ Inc (NASDAQ:BIVV).

Institutional Ownership by Quarter for Bioverativ (NASDAQ:BIVV)

Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit